Nurix Therapeutics Inc (NASDAQ:NRIX) — Market Cap & Net Worth
Market Cap & Net Worth: Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NASDAQ:NRIX) has a market capitalization of $1.93 Billion ($1.93 Billion) as of August 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6179 globally and #1960 in its home market, demonstrating a -2.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nurix Therapeutics Inc's stock price $23.21 by its total outstanding shares 101369235 (101.37 Million). See how much does Nurix Therapeutics Inc reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Nurix Therapeutics Inc Market Cap History: 2020 to 2026
Nurix Therapeutics Inc's market capitalization history from 2020 to 2026. Data shows growth from $3.33 Billion to $2.35 Billion (3.37% CAGR).
Index Memberships
Nurix Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.08% | #162 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #696 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.72 Trillion | 0.11% | #100 of 263 |
Weight: Nurix Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nurix Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nurix Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
35.01x
Nurix Therapeutics Inc's market cap is 35.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.33 Billion | $17.82 Million | -$43.24 Million | 187.04x | N/A |
| 2021 | $2.93 Billion | $29.75 Million | -$117.19 Million | 98.64x | N/A |
| 2022 | $1.11 Billion | $38.63 Million | -$166.04 Million | 28.81x | N/A |
| 2023 | $1.05 Billion | $76.99 Million | -$143.95 Million | 13.59x | N/A |
| 2024 | $1.91 Billion | $54.55 Million | -$193.57 Million | 35.01x | N/A |
Competitor Companies of NRIX by Market Capitalization
Companies near Nurix Therapeutics Inc in the global market cap rankings as of August 1, 2026.
Key companies related to Nurix Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Nurix Therapeutics Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Nurix Therapeutics Inc's market cap moved from $3.33 Billion to $ 2.35 Billion, with a yearly change of 3.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.35 Billion | +22.35% |
| 2025 | $1.92 Billion | +0.69% |
| 2024 | $1.91 Billion | +82.56% |
| 2023 | $1.05 Billion | -6.01% |
| 2022 | $1.11 Billion | -62.07% |
| 2021 | $2.93 Billion | -11.95% |
| 2020 | $3.33 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Nurix Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.93 Billion USD |
| MoneyControl | $1.93 Billion USD |
| MarketWatch | $1.93 Billion USD |
| marketcap.company | $1.93 Billion USD |
| Reuters | $1.93 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-ce… Read more